Soy isoflavones — genistein, daidzein and glycitein — are one of the most studied plant compounds in Japan, where soy foods have been part of the diet for centuries. Brands abroad ask for a soy isoflavone product because of that reputation, usually aimed at women past their thirties.
This guide is for brand owners planning a soy isoflavone product made in Japan. It covers what human trials show, the intake limits Japan’s food safety regulators set for supplements, how the ingredient is usually formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a soy isoflavone product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Meta-analyses of human trials show a fairly consistent reduction in hot flash frequency and severity, but modest and often non-significant results for bone density markers and blood lipids, and mixed results for other menopausal symptoms.
| Study | Design | Reported result |
|---|---|---|
| Meta-analysis, Menopause 2012;19(7):776–790 (PMID 22433977) | 17 randomised controlled trials pooled from a systematic review of extracted or synthesised soy isoflavones (median dose 54 mg/day, aglycone equivalents), 6 weeks to 12 months, in peri- and post-menopausal women | Hot flash frequency reduced by 20.6% and severity by 26.2% versus placebo |
| Systematic review and meta-analysis, Journal of Clinical Medicine 2022;11(16):4676 (PMID 36012916) | 18 randomised controlled trials, 2,350 postmenopausal women, isoflavone doses 40–300 mg/day (average 106 mg/day) | Small but statistically significant increases in bone mineral density at the lumbar spine (+1.63%), femoral neck (+1.87%) and total hip (+0.39%) versus control |
| Systematic review and meta-analysis, Nutrients 2021;13(8):2531 (PMID 34444691) | 29 randomised controlled trials (32 comparisons), 2,305 postmenopausal women, isoflavone doses 30.3–165 mg/day (median 80 mg/day), some arms combined with soy protein | Total cholesterol reduced significantly; small increase in HDL cholesterol at the border of significance; reductions in LDL cholesterol and triglycerides did not reach significance |
| Systematic review and meta-analysis, PeerJ 2025;13:e19715 (PMID 40718787) | 7 of 12 pooled trials specifically assessed menopausal symptoms, 533 perimenopausal women | Significant improvement in headache, psychosocial symptoms, palpitations and depression scores; no significant effect on hot flushes, sweating, insomnia or other vasomotor symptoms |
A few points worth keeping in view:
- Dose varies widely between trials — from about 30 mg to 300 mg of isoflavones a day, measured different ways (aglycone equivalents in some trials, total isoflavone weight in others). A dose that shows an effect in one trial does not automatically apply to a different amount or a different measurement basis.
- All four studies were run in peri- or post-menopausal women. That is a fact about who was studied, not a basis for marketing a product to treat any condition.
- Results are strongest and most consistent for hot flash frequency and severity, and weakest for blood lipids, where most of the individual outcomes in the 2021 meta-analysis did not reach statistical significance.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
Japan caps the isoflavone amount in tablet, capsule and powder-type health foods at 30 mg a day of isoflavone aglycone equivalent, under a 2006 Ministry of Health, Labour and Welfare guideline that built on a Food Safety Commission assessment of Foods for Specified Health Uses.
Two separate documents set the figures, both expressed as isoflavone aglycone equivalent:
- The Food Safety Commission’s May 2006 assessment covered Foods for Specified Health Uses (FOSHU) containing soy isoflavones. It set a total daily intake upper limit of 70–75 mg/day from all sources, and a safe upper limit of 30 mg/day for isoflavones taken from a FOSHU product on top of an ordinary diet. It also judged that taking such products on top of an ordinary diet is not recommended for pregnant women, infants or children. The Commission did not assess other health foods, but advised consumers to use the same thinking to avoid excessive intake.
- The Ministry of Health, Labour and Welfare’s August 2006 guideline (notice Shokuanhatsu No. 0823001) applied the 30 mg/day figure beyond FOSHU. Health foods in tablet, capsule, powder or liquid form that concentrate or fortify soy isoflavones should set the daily intake so that it does not exceed 30 mg of isoflavone aglycone, and label the content and intake precautions — including that pregnant or breastfeeding women, infants and children should not take the product, and that excessive intake should be avoided. Ordinary soy foods are outside the guideline.
Soy isoflavones also appear as the functional ingredient in Foods with Function Claims notified under Japan’s Consumer Affairs Agency system, with function wording describing a role in helping to maintain bone constituents — a function of a healthy skeletal system aimed at women who want to keep their bones strong, not a treatment claim. As with other Foods with Function Claims, the notifying business is responsible for the evidence and submits it before sale, and the amount used in the notified product is measured as isoflavone aglycone equivalent, consistent with the 2006 figures.
💬 Need an evidence summary for your regulatory adviser that separates Japan’s intake limits from the human trial data? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe soy isoflavones by what has been studied and at what dose, never as a hormone replacement or a treatment for menopause.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for hot flash frequency and severity" | "Menopause”, “hormone replacement” or any disease/condition name attached to the product |
| ”Contains [X] mg isoflavones (aglycone equivalent) per serving" | "Balances hormones” or “acts like oestrogen" |
| "Studied for bone density markers" | "Prevents osteoporosis” or “reverses bone loss” |
| Naming the study and its dose | ”Clinically proven” without naming the study and its limits |
How soy isoflavones are formulated
Soy isoflavones are dosed in tens of milligrams and are stable, water-soluble compounds once extracted, so they fit tablets, capsules and powder sticks equally well.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Tablet | Small, low cost per serving, easy to combine with other bone or beauty ingredients | Binder and disintegration for a consistent isoflavone release |
| Hard capsule | Simple, flavourless, fast to formulate | Fill weight for the target milligram dose |
| Soft capsule | Suits combination with oil-soluble ingredients | Shell material and dietary suitability |
| Powder stick or sachet | Fits a daily routine format, easy to combine with soy protein | Taste, since isoflavone extracts can be slightly bitter |
Decisions that shape the specification:
- Source and extract standardisation. Soy isoflavones for supplements are usually extracted from soybeans or soy germ and standardised to a guaranteed isoflavone content. Ask the supplier for the assay method and whether the content is expressed as aglycones, glucosides or total isoflavones — these are not the same number, and confusing them changes the actual dose.
- Daily amount, measured against Japan’s 30 mg/day supplement cap. For any product made or sold in Japan, the amount contributed by the supplement — on top of normal dietary intake — needs to stay within the Ministry of Health, Labour and Welfare’s 30 mg/day aglycone-equivalent limit for tablet, capsule and powder-type health foods, which sits inside the Food Safety Commission’s wider 70–75 mg/day total. Even for products sold only outside Japan, this figure is a useful reference point against the higher doses used in some trials.
- Soy allergen labelling. Soy is recognised as a major food allergen in most markets, including under the United States’ Food Allergen Labeling and Consumer Protection Act and the European Union’s allergen labelling rules. A soy isoflavone extract must be declared as a soy-derived ingredient on the label, and any shared-line cross-contact risk should be checked with the factory.
- Population wording. Because Japan’s 2006 guideline requires a label precaution that pregnant or breastfeeding women, infants and children should not take concentrated isoflavone products, keep any Japan-facing product and its marketing clearly aimed at adult women, and confirm your own market’s rules on the same point.
- Companion ingredients. Calcium, vitamin D, vitamin K2 and collagen peptide are common partners in bone- and beauty-themed formulas. Each companion ingredient needs its own check against Japanese food law.
- Market status. Soy isoflavone supplement rules differ by country — some markets set their own intake guidance, separate from Japan’s. Confirm your market’s position before you commit to a dose.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Soy isoflavone extracts used in foods are well established in Japan, and the main design decision is the daily amount rather than whether the ingredient itself is permitted. Companion botanicals in bone or beauty formulas are where problems more often arise. See the Japan-made supplement OEM page, and our hyaluronic acid and collagen peptide guides for two more examples of formulating for the same audience.
Before you ask for a quotation
A factory can quote accurately once the extract, the amount, the form and the packaging are fixed.
- Isoflavone source and standardisation, and whether the amount is expressed as aglycones, glucosides or total isoflavones
- Daily amount, checked against Japan’s 30 mg/day supplement cap if the product is made or sold in Japan
- Dosage form
- Soy allergen declaration and any cross-contact considerations at the factory
- Companion ingredients and their amounts
- Packaging
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made soy isoflavone product? Send us the concept — extract, daily amount, form and the countries you will sell in.
Frequently asked questions
1. What is Japan’s intake limit for soy isoflavone supplements?
Health foods in tablet, capsule, powder or liquid form that concentrate soy isoflavones should not exceed 30 mg a day of isoflavone aglycone equivalent, under a 2006 Ministry of Health, Labour and Welfare guideline. The figure comes from the Food Safety Commission’s 2006 assessment of Foods for Specified Health Uses, which also set a total daily intake ceiling of 70–75 mg from all sources.
2. Do soy isoflavones actually reduce hot flashes?
A 2012 meta-analysis of 17 randomised trials found a 20.6% reduction in hot flash frequency and a 26.2% reduction in severity versus placebo. This is one of the more consistent findings in the isoflavone literature, though results for other menopausal symptoms are mixed.
3. Is soy isoflavone a labelled allergen?
Yes. Soy is one of the major food allergens recognised in most markets, including the United States and the European Union, so a soy isoflavone extract needs to be declared on the label as a soy-derived ingredient.
4. What did EFSA conclude about isoflavone supplement safety?
In a 2015 opinion, EFSA’s Panel on Food Additives and Nutrient Sources added to Food reviewed human and animal data on isoflavone supplements in peri- and post-menopausal women, at the doses used in the studies it examined (roughly 35–150 mg/day), and found no clear evidence of an increased breast cancer risk, no adverse effect on the endometrium, and no effect on thyroid function. The panel did not set a single safe intake figure for isoflavones as a group, because effects varied between individual compounds and target organs.
5. Which dosage form suits soy isoflavones best?
Tablets, hard capsules, soft capsules and powder sticks are all used, since the daily amount is measured in tens of milligrams and the extract is stable once standardised. The choice usually comes down to what companion ingredients — calcium, vitamin K2 or collagen peptide, for example — are in the formula.
Sources: “Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials”, Menopause 2012;19(7):776–790 (PMID 22433977); “The Role of Soy Isoflavones in the Prevention of Bone Loss in Postmenopausal Women: A Systematic Review with Meta-Analysis of Randomized Controlled Trials”, Journal of Clinical Medicine 2022;11(16):4676 (PMID 36012916); “Effects of Soy Protein Containing of Isoflavones and Isoflavones Extract on Plasma Lipid Profile in Postmenopausal Women”, Nutrients 2021;13(8):2531 (PMID 34444691); “Effects of soy isoflavones on menopausal symptoms in perimenopausal women: a systematic review and meta-analysis”, PeerJ 2025;13:e19715 (PMID 40718787); Food Safety Commission of Japan, “Basic approach to the safety assessment of Foods for Specified Health Uses containing soy isoflavones”, May 2006 (fsc.go.jp); Ministry of Health, Labour and Welfare, guideline on the handling of Foods for Specified Health Uses and similar foods containing soy isoflavones, notice Shokuanhatsu No. 0823001, 23 August 2006; EFSA Panel on Food Additives and Nutrient Sources added to Food, “Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones”, EFSA Journal 2015;13(10):4246, doi 10.2903/j.efsa.2015.4246; Consumer Affairs Agency notifications for Foods with Function Claims. Checked on 12 October 2026.